PEBP4 gene expression in lung squamous cell carcinoma: A meta‑analysis‑based study of the molecular pathways involved

Yu,Guiping; Zhong,Ning; Huang,Bin; Mi,Yedong

doi:10.3892/ol.2020.11386

PEBP4 gene expression in lung squamous cell carcinoma: A meta‑analysis‑based study of the molecular pathways involved

Authors:
- Guiping Yu
- Ning Zhong
- Bin Huang
- Yedong Mi
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu 214400, P.R. China, Department of Cardiothoracic Surgery, The First People's Hospital of Kunshan, Kunshan, Jiangsu 215300, P.R. China
Published online on: February 12, 2020 https://doi.org/10.3892/ol.2020.11386
Pages: 2825-2831
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have suggested increased activity of phosphatidylethanolamine binding protein 4 (PEBP4) may be associated with the prognosis of non‑small cell lung cancer. However, to the best of our knowledge, no direct association between PEBP4 and lung squamous cell carcinoma (LSCC) has been reported. In the present study, a systematic review and meta‑analysis was performed to examine the gene expression activity of PEBP4 in LSCC. A total of 10 out of 131 gene expression datasets from the Gene Expression Omnibus (GEO) were selected, including 574 samples (319 patients with LSCC and 255 healthy controls). Subsequently, multiple linear regression (MLR) was employed to study three potential influencing factors: Sample size, population region and study date. A literature‑based pathway analysis was then conducted to examine the potential mechanisms through which PEBP4 may exert influence on LSCC. The results of a meta‑analysis indicated that, in LSCC, PEBP4 exhibited significantly low expression levels (P<0.033), with mildly increased gene expression levels observed in three studies (log fold‑change: 0.072‑2.13). However, a significant between‑study variance was observed from the heterogeneity analysis. MLR indicated that population region was a significant factor (P<0.0065), whereas sample size and study age were not (P>0.46). Eight functional pathways were subsequently identified, through which PEBP4 may influence the prognosis of LSCC and its response to treatment. The results of the present study suggested that the effects of PEBP4 on LSCC can be neglected in most cases of LSCC, where PEBP4 demonstrated decreased expression levels. However, in the case of PEBP4 overexpression, it may contribute to the progression of LSCC and lead to the development of drug resistance.

View Figures

View References

1	World Health Organization International Agency for Research on Cancer. GLOBOCAN 2012, . Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Default.aspxJan 27–2015
2	Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA and Iafrate AJ: FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 7:1775–1780. 2012. View Article : Google Scholar : PubMed/NCBI
3	Pirker R: What is the best strategy for targeting EGF receptors in non-small-cell lung cancer? Future Oncol. 11:153–167. 2015. View Article : Google Scholar : PubMed/NCBI
4	D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M and Kris MG: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 29:2066–2070. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG and Ladanyi M: Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 18:1167–1176. 2012. View Article : Google Scholar : PubMed/NCBI
6	Li W, Dong Y, Zhang B, Kang Y, Yang X and Wang H: PEBP4 silencing inhibits hypoxia-induced epithelial-to-mesenchymal transition in prostate cancer cells. Biomed Pharmacother. 81:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
7	Li P, Wang X, Li N, Kong H, Guo Z, Liu S and Cao X: Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways. Int J Mol Med. 18:505–510. 2006.PubMed/NCBI
8	Qiu J, Yang G, Lin A, Shen Z, Wang D and Ding L: Human phosphatidylethanolamine-binding protein 4 promoted the radioresistance of human rectal cancer by activating Akt in an ROS-dependent way. PLoS One. 9:e900622014. View Article : Google Scholar : PubMed/NCBI
9	Yu G, Huang B, Chen G and Mi Y: Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K/Akt/mTOR axis. J Thorac Dis. 7:1806–1816. 2015.PubMed/NCBI
10	Nazarov PV, Muller A, Kaoma T, Nicot N, Maximo C, Birembaut P, Tran NL, Dittmar G and Vallar L: RNA sequencing and transcriptome arrays analyses show opposing results for alternative splicing in patient derived samples. BMC Genomics. 18:4432017. View Article : Google Scholar : PubMed/NCBI
11	Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
12	Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
13	Schuster K, Venkateswaran N, Rabellino A, Girard L, Peña-Llopis S and Scaglioni PP: Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis. Mol Cancer Res. 12:912–923. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kahn N, Meister M, Eberhardt R, Muley T, Schnabel PA, Bender C, Johannes M, Keitel D, Sültmann H, Herth FJ and Kuner R: Early detection of lung cancer by molecular markers in endobronchial epithelial-lining fluid. J Thorac Oncol. 7:1001–1008. 2012. View Article : Google Scholar : PubMed/NCBI
15	Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 5:e103122010. View Article : Google Scholar : PubMed/NCBI
16	Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S, Ushijima M, Matsuura M, Jones MH, Shimane M, et al: ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. Lung Cancer. 75:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
17	Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T and Takahashi T: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 24:1679–988. 2006. View Article : Google Scholar : PubMed/NCBI
18	Matsuyama Y, Suzuki M, Arima C, Huang QM, Tomida S, Takeuchi T, Sugiyama R, Itoh Y, Yatabe Y, Goto H and Takahashi T: Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Mol Carcinog. 50:301–309. 2011. View Article : Google Scholar : PubMed/NCBI
19	Boelens MC, van den Berg A, Fehrmann RS, Geerlings M, de Jong WK, te Meerman GJ, Sietsma H, Timens W, Postma DS and Groen HJ: Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol. 218:182–191. 2009. View Article : Google Scholar : PubMed/NCBI
20	Borenstein M, Hedges LV, Higgins JP and Rothstein HR: A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 1:97–111. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li F, Fang Z, Zhang J, Li C, Liu H, Xia J, Zhu H, Guo C, Qin Z, Li F, et al: Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Res. 26:1149–1164. 2016. View Article : Google Scholar : PubMed/NCBI
22	Jian W, Bai Y, Li X, Kang J, Lei Y and Xue Y: Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway. J Cell Biochem. 120:5386–5395. 2019. View Article : Google Scholar : PubMed/NCBI
23	An LP, Maeda T, Sakaue T, Takeuchi K, Yamane T, Du PG, Ohkubo I and Ogita H: Purification, molecular cloning and functional characterization of swine phosphatidylethanolamine-binding protein 4 from seminal plasma. Biochem Biophys Res Commun. 423:690–696. 2012. View Article : Google Scholar : PubMed/NCBI
24	Li H, Wang X, Li N, Qiu J, Zhang Y and Cao X: hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J Biol Chem. 282:4943–4950. 2007. View Article : Google Scholar : PubMed/NCBI
25	Li H, Chen F, Yu L, Liu M, Chen H, Zhang Y and Liu X: Expression of inflammation related enzymes during experimental rat lung carcinogenesis. Zhonghua Zhong Liu Za Zhi. 24:316–319. 2002.PubMed/NCBI
26	Weeden CE, Ah-Cann C, Holik AZ, Pasquet J, Garnier JM, Merino D, Lessene G and Asselin-Labat ML: Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Oncogene. 37:4475–4488. 2018. View Article : Google Scholar : PubMed/NCBI
27	Aruga N, Kijima H, Masuda R, Onozawa H, Yoshizawa T, Tanaka M, Inokuchi S and Iwazaki M: Epithelial-mesenchymal transition (EMT) is correlated with patient's prognosis of lung squamous cell carcinoma. Tokai J Exp Clin Med. 43:5–13. 2018.PubMed/NCBI
28	Yu G, Shen Z, Chen G, Teng X, Hu Y and Huang B: PEBP4 enhanced HCC827 cell proliferation and invasion ability and inhibited apoptosis. Tumour Biol. 34:91–98. 2013. View Article : Google Scholar : PubMed/NCBI